Good Clinical Practice (GCP) is not a suggestion — it is the internationally recognised ethical and scientific quality standard that governs the design, conduct, recording, and reporting of clinical trials. Failure to comply can result in invalidated data, regulatory sanctions, and, most critically, harm to trial participants. As protocols grow more complex and regulatory agencies sharpen their audit focus in 2025, research sites must be more proactive than ever about GCP readiness. This guide outlines the key compliance pillars every site must have in place — and how MD Trials helps sites achieve them.
What GCP Compliance Actually Means at the Site Level
GCP compliance encompasses a broad range of practices, from how informed consent is obtained and documented, to how source data is collected, how adverse events are reported, and how investigator oversight is maintained. The ICH E6(R2) guidelines — and the forthcoming E6(R3) revision — serve as the global benchmark for these standards.
The Five Pillars of Site-Level GCP Compliance
- Informed Consent Management: Every participant must provide documented, voluntary, informed consent prior to any study procedure. Consent must be re-obtained whenever the protocol or risk profile changes.
- Investigator Oversight: The Principal Investigator bears ultimate responsibility for trial conduct. Sites must ensure adequate delegation of duties and proper oversight of all delegated tasks.
- Source Data Integrity: All data must be attributable, legible, contemporaneous, original, accurate, and complete (ALCOA+). Alterations to source data must be traceable.
- Adverse Event Reporting: Sites must have clear procedures for identifying, grading, and reporting adverse events and serious adverse events within protocol and regulatory deadlines.
- Regulatory Document Management: The Investigator Site File (ISF) must be maintained, organised, and audit-ready at all times throughout the trial and for the required retention period post-trial.
Common GCP Deficiencies Found During Inspections
Regulatory agencies and sponsor monitors consistently identify the same recurring deficiencies: incomplete consent documentation, protocol deviations without documented corrective actions, disorganised ISFs, inadequate delegation logs, and delayed adverse event reporting. Each of these is preventable with proper systems and training.
How MD Trials Keeps Sites Audit-Ready
MD Trials implements site-specific SOPs aligned with ICH-GCP and Health Canada requirements. Our team conducts internal readiness audits, provides ongoing staff training, manages regulatory document filing, and supports sites through sponsor monitoring visits and regulatory inspections — ensuring compliance is never reactive.
EXPERT INSIGHT: The ICH E6(R3) revision, currently being finalised, places increased emphasis on risk-based approaches and electronic systems governance — signalling that GCP compliance will require even more systematic, documented site processes in the years ahead.
Frequently Asked Questions (FAQ)
Q: What is the difference between ICH-GCP and Health Canada regulations?
A: ICH-GCP (E6) is an international guideline adopted by most major regulatory agencies, including Health Canada. Health Canada’s Division 5 regulations for clinical trials are largely harmonised with ICH-GCP, but sites in Canada must comply with both.
Q: How often should a research site conduct internal GCP audits?
A: Best practice is at least annually — or before each new study activation. MD Trials recommends quarterly compliance reviews for high-volume sites to catch issues before they escalate.
Q: Can protocol deviations affect regulatory approval of a drug?
A: Yes. Significant or systematic protocol deviations can raise questions about data reliability during regulatory review, potentially delaying or jeopardising marketing approval.
No comment